Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 6, 2008, Pages 1365-1371

  Rabinovitch, Nathan ^a   Strand, Matthew ^a   Stuhlman, Kate ^a   Gelfand, Erwin W ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE

Author keywords

Asthma; children; cysteinyl leukotrienes; FENO; LTE4; montelukast

Indexed keywords

COTININE; LEUKOTRIENE E4; MONTELUKAST; NITRIC OXIDE; PEPTIDOLEUKOTRIENE; PLACEBO; SALBUTAMOL; TOBACCO SMOKE;

ADOLESCENT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG MONITORING; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE;

ACETATES; ADOLESCENT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; BRONCHODILATOR AGENTS; CHILD; COTININE; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE E4; MALE; NITRIC OXIDE; QUINOLINES; SEX FACTORS; TOBACCO SMOKE POLLUTION;

EID: 44649161234     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.03.016     Document Type: Article

References (40)

1. Doucet M.Y., Jones T.R., and Ford-Hutchinson A.W. Responses of equine trachealis and lung parenchyma to methacholine, histamine, serotonin, prostanoids, and leukotrienes in vitro. Can J Physiol Pharmacol 68 (1990) 379-383
2. Gyllfors P., Kumlin M., Dahlén S.E., Gaber F., Ehrs P.O., and Dahlen B. Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. Thorax 60 (2005) 902-908
3. Busse W., and Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 127 (2005) 1312-1326
4. Kanwar S., Johnston B., and Kubes P. Leukotriene C4/D4 induces P-selectin and sialyl Lewis (x)-dependent alterations in leukocyte kinetics in vivo. Circ Res 77 (1995) 879-887
5. Barnes N., Thomas M., Price D., and Tate H. The National Montelukast Survey. J Allergy Clin Immunology 115 (2005) 47-54
6. Becker A., Swern A., Tozzi C.A., Yu Q., Reiss T., and Knorr B. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin 20 (2004) 1651-1659
7. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005) 233-242
8. Johnston N.W., Mandhane P.J., Dai J., Duncan J.M., Greene J.M., Lambert K., et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 120 (2007) 702-712
9. Lazarus S.C., Chinchilli V.M., Rollings N.J., Boushey H.A., Cherniack R., Craig T.J., et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 175 (2007) 783-790
10. Cai C., Yang J., Hu S., Zhou M., and Guo W. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung 185 (2007) 105-112
11. Dahlén S.E., Malmström K., Nizankowska E., Dahlén B., Kuna P., Kowalski M., et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 9-14
12. Rabinovitch N., Zhang L., and Gelfand E.W. Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. J Allergy Clin Immunol 118 (2006) 635-640
13. Westcott J.Y., Maxey K.M., Macdonald J., and Wenzel S.E. Immunoaffinity resin for purification of urinary leukotriene E4. Prostaglandins Other Lipid Mediat 55 (1998) 301-321
14. North L.M., Gaudette N.D., Cordeiro M.L., Fitchen J.H., Davidson S.L., and Hindahl M.S. Detection of cotinine in oral fluid recovered with the OraSure collection system. Ann N Y Acad Sci 694 (1993) 332-333
15. Buchvald F., Baraldi E., Carraro S., Gaston B., De Jongste J., Pijnenburg M.W., et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. J Allergy Clin Immunol 115 (2005) 1130-1136
16. Dobson A.J. An introduction to generalized linear models. 2nd ed. (2001), Chapman & Hall/CRC, Boca Raton (FL)
17. Kauermann G., and Carroll R.J. A note on the efficiency of sandwich covariance matrix estimation. J Am Stat Assoc 96 (2001) 1387-1398
18. Lu B., Preisser J.S., Qaqish B.F., Suchindran C., Bangdiwala S.I., and Wolfson M. A comparison of two bias-corrected covariance estimators for generalized estimating equations. Biometrics 63 (2007) 935-941
19. Rabinovitch N., Strand M., and Gelfand E.W. Particulate levels are associated with early asthma worsening in children with persistent disease. Am J Respir Crit Care Med 173 (2006) 1098-1105
20. Zeiger R.S., Szefler S.J., Phillips B.R., Schatz M., Martinez F.D., Chinchilli V.M., et al. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 117 (2006) 45-52
21. Kurokawa K., Tanaka H., Tanaka S., and Abe S. Circadian characteristics of urinary leukotriene E (4) in healthy subjects and nocturnal asthmatic patients. Chest 120 (2001) 1822-1828
22. Bellia V., Bonanno A., Cibella F., Cuttitta G., Mirabella A., Profita M., et al. Urinary leukotriene E4 in the assessment of nocturnal asthma. J Allergy Clin Immunol 97 (1996) 735-741
23. Chalmers G.W., MacLeod K.J., Thomson L., Little S.A., McSharry C., and Thomson N.C. Smoking and airway inflammation in patients with mild asthma. Chest 120 (2001) 1917-1922
24. Chalmers G.W., Macleod K.J., Little S.A., Thomson L.J., McSharry C.P., and Thomson N.C. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 57 (2002) 226-230
25. Smith C.M., Hawksworth R.J., Thien F.C., Christie P.E., and Lee T.H. Urinary leukotriene E4 in bronchial asthma. Eur Respir J 5 (1992) 693-699
26. Misso N.L., Aggarwal S., Phelps S., Beard R., and Thompson P.J. Urinary leukotriene E4 and 9 alpha, 11 beta-prostaglandin F concentrations in mild, moderate and severe asthma, and in healthy subjects. Clin Exp Allergy 34 (2004) 624-631
27. Strunk R.C., Szefler S.J., Phillips B.R., Zeiger R.S., Chinchilli V.M., Larsen G., et al. Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 113 (2004) 789-790
28. Early S.B., Barekzi E., Negri J., Hise K., Borish L., and Steinke J.W. Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells. Am J Respir Cell Mol Biol 36 (2007) 715-720
29. Reid D.W., Johns D.P., Feltis B., Ward C., and Walters E.H. Exhaled nitric oxide continues to reflect airway hyperresponsiveness and disease activity in inhaled corticosteroid-treated adult asthmatic patients. Respirology 8 (2003) 479-486
30. Fauler J., and Frolich J.C. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 27 (1997) 43-47
31. Warke T.J., Mairs V., Fitch P.S., Ennis M., and Shields M.D. Possible association between passive smoking and lower exhaled nitric oxide in asthmatic children. Arch Environ Health 58 (2003) 613-616
32. Nordvall S.L., Janson C., Kalm-Stephens P., Foucard T., Torén K., and Alving K. Exhaled nitric oxide in a population-based study of asthma and allergy in schoolchildren. Allergy 60 (2005) 469-475
33. Ducharme F.M., and Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 1 (2004) CD002314
34. Heaney L.G., and Robinson D.S. Severe asthma treatment: need for characterising patients. Lancet 365 (2005) 974-976
35. Manso G., Baker A.J., Taylor I.K., and Fuller R.W. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur Respir J 5 (1992) 712-716
36. O'Shaughnessy K.M., Wellings R., Gillies B., and Fuller R.W. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 147 (1993) 1472-1476
37. Ram F.S.F., Cates C.J., and Ducharme F.M. Long acting beta-2 agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 1 (2005) CD003137
38. Ilowite J., Webb R., Friedman B., Kirwin E., Bird S.R., Hustad C.M., et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 92 (2004) 641-648
39. Bjermer L., Bisgaard H., Bousquet J., Fabbri L.M., Greening A.P., Haahtela T., et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 327 (2003) 891
40. Delfino R.J. Who are the children with asthma most susceptible to air pollution?. Am J Respir Crit Care Med 173 (2006) 1054-1055